Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1982-03-01
1985-01-29
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514359, 514256, 514258, 514406, 514361, 514364, 514365, 514374, 514383, 514396, 544317, 544327, 544328, 544329, 546275, 546276, 516277, 516278, 516279, 548128, 548130, 548132, 548133, 548184, 548194, 548232, 548236, 548255, 548265, 548266, 548337, 548377, C07D24904, C07D40112, A01K 3141
Patent
active
044965710
ABSTRACT:
The invention relates to carbonyl derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention where is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.5 -E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO.sub.2 or NR.sup.6 in which R.sup.6 is H or 1-6C alkyl, R.sup.5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.5 and R.sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is H and R.sup.1 is H, 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; D is O or S; R.sup.4 is H or 1-6C alkyl; R.sup.3 is H or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.
REFERENCES:
patent: 4165377 (1979-08-01), Jones et al.
patent: 4165378 (1979-08-01), Gilman et al.
patent: 4234735 (1980-11-01), Jones et al.
patent: 4242350 (1980-12-01), Yellin et al.
patent: 4242351 (1980-12-01), Yellin et al.
patent: 4262126 (1981-04-01), Gilman et al.
patent: 4315009 (1982-02-01), Jones et al.
patent: 4332949 (1982-06-01), Yellin et al.
patent: 4338447 (1982-07-01), Yellin et al.
patent: 4338448 (1982-07-01), Yellin et al.
patent: 4342765 (1982-08-01), Jones et al.
patent: 4362728 (1982-12-01), Yellin
Edwards Philip N.
Gilman David J.
Jones Derrick F.
Large Michael S.
Oldham Keith
Gerstl Robert
ICI Americas Inc.
Imperial Chemical Industries PLC
LandOfFree
Histamine H2-antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histamine H2-antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histamine H2-antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-506284